Large Inflow of Money Detected in Gilead Sciences

Gilead Sciences (GILD) : Tuesdays money flow data in Gilead Sciences (GILD) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $143.73 million, whereas, $137.81 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.04, in favor of the bulls. The total money flow into the stock was $5.92 million clearly indicating that the smart money has been buying into the stock on weakness.

In comparison, the money flow in block deals was $2.95 million. The total value of block trades done on upticks was $37.81 million. The value of bearish trades on downticks was only $34.86 million.The up/down ratio in the block trades was a healthy 1.08 in favor of the bulls, suggesting strong buying in the stock by large traders. Gilead Sciences (GILD) fell $0.25 and traded at $77.92, down -0.32% for the day, over previous days close. On a weekly basis, the shares are -2.32% over the previous weeks close.


Also, In the latest statement by the brokerage house, Argus Research downgrades its outlook on Gilead Sciences (NASDAQ:GILD). The current rating of the shares is Hold, according to the research report released by the firm. Previously, the company had a rating of Buy. The rating by the firm was issued on July 29, 2016.

Gilead Sciences Inc. has lost 4.36% in the last five trading days and dropped 3.16% in the last 4 weeks. Gilead Sciences Inc. has dropped 9.5% during the last 3-month period . Year-to-Date the stock performance stands at -22.19%.

Gilead Sciences (NASDAQ:GILD): The stock opened at $78.05 on Tuesday but the bulls could not build on the opening and the stock topped out at $78.39 for the day. The stock traded down to $77.66 during the day, due to lack of any buying support eventually closed down at $77.92 with a loss of -0.32% for the day. The stock had closed at $78.17 on the previous day. The total traded volume was 9,174,195 shares.

In a related news,The director officer (President and CEO) of Gilead Sciences Inc, Milligan John F sold 70,000 shares at $70.94 on August 1, 2016. The Insider selling transaction had a total value worth of $4,965,800. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.